Skip to main navigation

About
Platform
Pipeline
- MDNA11
- BiSKITs
- MDNA55
Clinical Trials
Investor Relations
- News & Events
- Stock Information
  - Stock Quote & Chart
  - Analyst Coverage
- Corporate Governance
- Financials & Filings
  - Annual General Meeting
  - Financial Reports
- IR Resources

Careers
Contact

Investor Relations

Scientific Presentations

Categories

Neoadjuvant Administration of MDNA11, A Long-Acting IL-2 Superkine, Prevents Metastasis, Protects Against Tumor Rechallenges and Provides Long-Term Survival in an Orthotopic Model of Breast Cancer

Neoadjuvant Administration of MDNA11, A Long-Acting IL-2 Superkine, Prevents Metastasis, Protects Against Tumor Rechallenges and Provides Long-Term Survival in an Orthotopic Model of Breast Cancer

Source

2024 San Antonio Breast Cancer Symposium (SABCS)

Neoadjuvant Administration of MDNA11, A Long-Acting IL-2 Superkine, Prevents Metastasis, Protects Against Tumor Rechallenges and Provides Long-Term Survival in an Orthotopic Model of Breast Cancer

Neoadjuvant Administration of MDNA11, A Long-Acting IL-2 Superkine, Prevents Metastasis, Protects Against Tumor Rechallenges and Provides Long-Term Survival in an Orthotopic Model of Breast Cancer

Source

2024 San Antonio Breast Cancer Symposium (SABCS)

Updated Safety and Efficacy Results from the First-in-Human Study of MDNA11 (ABILITY-1), a Next Generation ‘Beta-Enhanced Not-Alpha’ IL-2 Superkine, Show Single-Agent Activity in Patients with Advanced Solid Tumors

Updated Safety and Efficacy Results from the First-in-Human Study of MDNA11 (ABILITY-1), a Next Generation ‘Beta-Enhanced Not-Alpha’ IL-2 Superkine, Show Single-Agent Activity in Patients with Advanced Solid Tumors

Source

Immunotherapy Bridge 2024

Invigorating Effector Immune Cells With Highly Selective IL-2R Agonists and Potential Synergy With Tumor Targeting Therapeutics for Treatment of Glioblastomas

Invigorating Effector Immune Cells With Highly Selective IL-2R Agonists and Potential Synergy With Tumor Targeting Therapeutics for Treatment of Glioblastomas

Invigorating Effector Immune Cells With Highly Selective IL-2R Agonists and Potential Synergy With Tumor Targeting Therapeutics for Treatment of Glioblastomas

Invigorating Effector Immune Cells With Highly Selective IL-2R Agonists and Potential Synergy With Tumor Targeting Therapeutics for Treatment of Glioblastomas

Results from ABILITY-1 Monotherapy Dose Escalation and Ongoing Monotherapy Expansion with MDNA11, a Long-acting ‘Beta-enhanced Not-alpha’ IL-2 Superkine, in Patients with Advanced Solid Tumors

Results from ABILITY-1 Monotherapy Dose Escalation and Ongoing Monotherapy Expansion with MDNA11, a Long-acting ‘Beta-enhanced Not-alpha’ IL-2 Superkine, in Patients with Advanced Solid Tumors

Source

Source: SITC 2024

MDNA113, an IL-13Rα2 Tumor Targeting and Conditionally Activatable anti-PD1-IL-2 BiSKIT Shows Enhanced Safety and Potent Therapeutic Efficacy

MDNA113, an IL-13Rα2 Tumor Targeting and Conditionally Activatable anti-PD1-IL-2 BiSKIT Shows Enhanced Safety and Potent Therapeutic Efficacy

Results from Monotherapy Dose Escalation of MDNA11

Results from Monotherapy Dose Escalation of MDNA11

Source

Source: SITC 2024

MDNA113, an IL-13Rα2 Tumor Targeting and Conditionally Activatable anti-PD1-IL-2SK BiSKIT Shows Enhanced Safety and Potent Therapeutic Efficacy

Source

Promise IL2 Therapy 2024

MDNA209, a High Affinity IL-2β Biased IL-2/IL-15 Super-antagonist, for the Treatment of Autoimmune Diseases

Source

Promise IL2 Therapy 2024

Phase 2b Study of Bizaxofusp- ASCO Annual Meeting 2024

Source

ASCO 2024

Results from Monotherapy Dose Escalation of MDNA11, a Long-acting IL-2 Superkine, in a Phase 1/2 Trial Show Evidence of Single-agent Activity in Advanced Solid Tumors

Results from Monotherapy Dose Escalation of MDNA11, a Long-acting IL-2 Superkine, in a Phase 1/2 Trial Show Evidence of Single-agent Activity in Advanced Solid Tumors

Source

AACR 2024

Results from Monotherapy Dose Escalation of MDNA11

Results from Monotherapy Dose Escalation of MDNA11

Source

AACR 2024

AACR 2024 - MDNA113

AACR 2024 - MDNA113

Characterization of MDNA113, a Tumor-Targeting Anti-PD1-IL-2 SK Immunocytokine with Conditional Activation to Increase Tolerability and Maximize Efficacy

Source

2024 AACR

Overall Survival of Recurrent Glioblastoma (rGBM) in Patients on Bizaxofusp (MDNA55), an IL-4R Targeting Toxin – Phase 2b Study

Source

2023 SNO

Overall Survival of Recurrent Glioblastoma (rGBM) in Patients on Bizaxofusp (MDNA55), an IL-4R Targeting Toxin – Phase 2b Study

Source

2023 SNO

Interim PK/PD, Safety and Efficacy Data of Monotherapy Dose Escalation of a Phase 1/2 Trial With MDNA11 in Patients With Advanced Solid Tumors

Source

38th Annual Meeting of the Society for Immunotherapy Cancer (SITC)

Interim PK/PD, Safety and Efficacy Data of Monotherapy Dose Escalation of a Phase 1/2 Trial With MDNA11 in Patients With Advanced Solid Tumors

Source

38th Annual Meeting of the Society for Immunotherapy Cancer (SITC)

Characterization of a Tumor-targeting and Activatable T-MASK Platform to Enhance Tumor Accumulation and Tolerability of Potent Immune Modulators

Source

38th Annual Meeting of the Society for Immunotherapy Cancer (SITC)

Characterization of a Tumor-targeting and Activatable T-MASK Platform to Enhance Tumor Accumulation and Tolerability of Potent Immune Modulators

Source

38th Annual Meeting of the Society for Immunotherapy Cancer (SITC)

Synergistically Engaging a b-Selective IL-2 Agonist with PD-1/PDL-1 Blockade in a Bifunctional Superkine, MDNA223

Source

023 AACR Special Meeting in Cancer Research: Tumor Immunology and Immunotherapy

Presentation Cover Image

Clinical Update from Phase 1/2 ABILITY Study

Source

R&D day, 2023

Presentation Cover Image

Planning of a Phase 3 Randomized Controlled Trial Incorporating an External Control Arm

Source

National Brain Tumor Society, 2023

Presentation Cover Image

Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment

Source

American Association for Cancer Research (AACR) Annual Meeting, 2023

Presentation Cover Image

Early Results of an IL-2 Superkine (MDNA11) from the Phase 1/2 ABILITY Study in Advanced Solid Tumors

Source

2023 Immunotherapy Bridge Conference, 2022

Presentation Cover Image

The Promise of Interlukin-2 Therapy Conference

Source

The Promise of IL-2 Therapy (Paris, France), 2022

Presentation Cover Image

Co-Stimulation of Adaptive and Innate Immune Cells to Achieve Clinical Benefit with MDNA11, a Long-Acting ‘Betaonly’ IL-2 Super-Agonist

Source

Cytokine Based Drug Development Summit, 2022

Presentation Cover Image

MDNA11 is a Long-Acting ‘Beta-Only’ IL-2 Agonist Exhibiting Potent Tumor Growth Control in Preclinical Models and Preferential Expansion of NK and CD8+ T Cells in Patients with Advanced Solid Tumors

Source

Frontiers in Cancer Immunotherapy 2022

Presentation Cover Image

MDNA11 Phase 1/2 ABILITY Study in Advanced Solid Tumors

Source

12th Annual LifeSci Partners Corporate Access Event, 2022

Presentation Cover Image

MDNA11 is a Long-Acting ‘Beta-Only’ IL-2 Agonist that Demonstrates Safe and Durable Anti-Tumor Immune Response

Source

AACR-NCI-EORTC Virtual International Conference On Molecular Targets and Cancer Therapeutics, 2021

Presentation Cover Image

Evolutionary IL-2 Superkines: Past, Present and Future

Source

Next-Gen Cytokine Therapeutics Summit, 2021

Presentation Cover Image

MDNA55 survival in recurrent glioblastoma ("rGBM") patients expressing the interleukin-4 receptor ("IL4R") as compared to a matched synthetic control

Source

2021

Presentation Cover Image

Modulation of Immune Responses to Cancer With Bi-specific IL-2/IL-13 Superkines

Source

American Association for Cancer Research (AACR) Annual Meeting, 2022

Presentation Cover Image

Designer cytotoxins

Source

Cytokine-Based Cancer Immunotherapies Summit, 2021

Presentation Cover Image

MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme

Source

KOL day, 2020

Presentation Cover Image

MDNA55, an IL4-Guided Toxin in Recurrent GBM: Phase 2b Results and Use of an External Control Arm in a Registration Trial

Source

3rd Annual Glioblastoma Drug Development Summit, 2020

Presentation Cover Image

Designer Superkines: Modulating Immune Cells of Choice

Source

Next-Gen Cytokine Therapeutics Summit, 2020

Presentation Cover Image

In vitro and in vivo characteristics of MDNA11: A long-acting 'Beta-only' IL-2 Superkine in syngeneic mice tumor models and non-human primates

Source

ASCO, 2020

Presentation Cover Image

IL-2 Superkine, MDNA19, Non-Human Primate Study

Source

webcast, 2020

Presentation Cover Image

Using a Multi-pronged Approach to Treating Recurrent GBM – Overcoming the Tumor and its Microenvironment

Source

Inaugural Glioblastoma Drug Development Annual Summit, 2019

Results from Monotherapy Dose Escalation of MDNA11

Results from Monotherapy Dose Escalation of MDNA11

Source

Source: SITC 2024

RSS Feeds

Print Page

Email Alerts

Document Request

© Copyright 2024 Medicenna Therapeutics

Terms of Use
Privacy Policy

Follow Us